Encouraging research and development of new products through employee initiatives and strategic alliances is key to serving and anticipating the changing needs of customers and patients.
Full Prescribing Information
Healthcare Professional Website
Patient Website
LIVALO is a registered trademark of the Kowa group of companies.
Full Prescribing Information, including Boxed Warning regarding addiction, abuse and misuse
Medication Guide
Healthcare Professional Website
To ensure that the benefits of opioid analgesics, including SEGLENTIS, outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers.
To obtain further information on the opioid analgesic REMS and for a list of accredited REMS continuing education, call 1-800-503-0784, or log on to www.opioidanalgesicrems.com.
SEGLENTIS is a registered trademark of Esteve Pharmaceuticals, S.A., and is used under license.
Kowa’s Research & Development activities are carried out at the company’s laboratories in Tokyo and Fuji. The focus is on lifestyle-related diseases, immune disorders and allergy, and dermatology and ophthalmology.
Kowa Research Institute is responsible for the United States development of Kowa’s new drug candidates. Kowa has several drugs currently in Phase I or later clinical development, for conditions such as dyslipidemia, type 2 diabetes mellitus and cancer. Please click here for an overview of Kowa’s drug candidates currently in Phase I or later clinical development.
Established in 1894, Kowa Company, Ltd. is actively engaged in various manufacturing and commercial activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products.
For more information, please visit the Kowa Company, Ltd. products website.
